Although record sums of venture capital were invested in early-stage companies in the United States last year, in reality it is very difficult to raise money this way. This is particularly true for life-science and physics-based start-ups, where money is available on only a highly selective basis.
“Venture capital has a very useful but specific role, and unless you fit that set of screening criteria you're not an option,” says David Gibson, president of X-ray Optical Systems (see boxoverleaf). He says venture capitalists are often reluctant to invest smaller amounts of money in very early-stage ventures, because it can take as much time and effort to invest $100,000 as to invest $10 million.
This is a preview of subscription content, access via your institution